GSK_ Annual_Report_2021-22

85 4. Details of complaints with regard to conflict of interest: All related party transactions are pre-approved by the Audit Committee and the Board of Directors. Any significant transaction is pre-approved by the Board of Directors and shareholders of your company as required by regulatory requirements. No complaints with regard to conflict of interest were received in FY 2021-22. Leadership Indicators 1. Awareness programmes conducted for value chain partners on any of the Principles during the financial year: • Specific third parties who interact with the Government on your company’s behalf undergo online ABAC trainings. Your company also conducts customized, case study-based trainings for such third parties • Two Employee Health and Safety trainings were conducted during the year for all third-party contract manufacturers. The virtual trainings were conducted on fire safety and electrical safety. • Further, awareness programmes on “Water Kaizen” (brainstorming on various water saving initiatives) and antimicrobial resistance (e.g., permissible discharge limits) are regularly conducted amongst key third-party contract manufacturers. • All third-party contract manufacturers receive communication on your company’s business responsibility policies such as the Code of Conduct, prevention of sexual harassment, and Standard Operating Procedures (SOPs) for health and safety. 2. Processes in place to avoid/ manage conflict of interests involving members of the Board Your company’s approach to avoiding/managing conflict of interests involving members of the Board is embodied within our Code of Conduct. Your company assesses all its activities for potential conflicts and ensures that any actual, potential, or perceivable conflicts are declared and resolved before the initiation of any task or project. The policy can be accessed at GSK Code of Conduct. Further, the Board of Directors sign off on Code of Conduct on an annual basis and a “No conflict of interest” declaration is obtained from the Board of Directors. Further, the Board confirms that there were no materially significant related party transactions made with the Promoters, Directors or Key Managerial Personnel which may have a potential conflict of interest with the company at large. 3.2. Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe Your company is committed to quality, safety and reliable supply of our products for patients and consumers. From the sourcing of raw materials to the manufacturing and marketing of the products, we make sure that effective quality management practices are strictly followed during all stages of the supply chain. We put our patient’s and consumers’ safety first. As a responsible entity, we have extensive controls in place to detect, evaluate, and communicate benefits, risks, and potential safety concerns about our products. Hence, we make sure that up- to-date relevant information is available on the packaging. Our procedures comply with Good Manufacturing Practice (GMP) regulations and other good practice procedures for ensuring Product Quality, and these are documented in the GSK Quality Management System. Compliance with GMP enables us to ensure that the medicinal products are consistently produced and controlled to the highest quality standards. Responding to the unprecedented challenges during the pandemic, the warehouse and distribution team moved with agility, collaborating with our vast network of stockists, warehouses, and manufacturing facilities. This not only improved access to quality healthcare, but also ensured that the supply chain network was not disrupted during the lockdown period(s). The warehousing and distribution network comprising 22 CMOs, 26 warehouses and 6,000 stockists continued to provide high levels of customer service on time. We continued to implement automation and digitalisation initiatives and driving excellence every step of the way to pharmacies, healthcare professionals’ clinics and patients. Our efforts are always directed at positively impacting patient health outcomes. An example of this was the launch of Nucala auto-injector formulation that enables patients to self-administer Nucala without the need for hospital visits. The auto-injector provided much needed compliance and ease during the pandemic-induced travel restrictions.